The Hidden Winner of the FDA's Anti-Generic Decision

In this video, Motley Fool health-care analyst David Williamson discusses the hidden winner of today's big FDA decision not to approve generic OxyContin despite a patent running out this week.

Big Pharma Pfizer sells an abuse-resistant, instant-acting version that will now avoid generic competition, but the hidden winner is the company whose technology makes the drug possible -- Acura Pharmaceuticals. This small cap popped more than 50% intraday, before settling with a 33% gain. Watch and find out what this means for investors.

What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

The article The Hidden Winner of the FDA's Anti-Generic Decision originally appeared on

David Williamson owns shares of Pfizer. Follow David on Twitter @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story